Prosecution Insights
Last updated: November 04, 2026
Application No. 18/854,401

AUTO-INJECTOR SYSTEM

Non-Final OA §102§112
Filed
Oct 04, 2024
Priority
Apr 06, 2022 — provisional 63/362,597 +1 more
Examiner
NGUYEN, CAMTU TRAN
Art Unit
3786
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Meridian Medical Technologies LLC
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
1y 6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
550 granted / 870 resolved
-6.8% vs TC avg
Strong +39% interview lift
Without
With
+38.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
19 currently pending
Career history
895
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
42.5%
+2.5% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
28.3%
-11.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 870 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Drawings The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, a second compressed spring (claims 7 & 14) and a separator (claim 1) must be shown or the feature(s) canceled from the claim(s). No new matter should be entered. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim 4 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 4 recites the limitation "the plunger" in lines 3 & 4. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-26 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Edwards (US 2013/0317477). Regarding independent claim 1, Edwards discloses applicant’s claimed reconstitution auto-injector (3000), comprising a body (housing 3100) having: a first chamber (medicament volume 3237) configured to store a powder therein; a second chamber (diluent volume 3236) configured to store a liquid. Regarding claim 2, Edwards reference, presented above, discloses applicant’s claimed reconstitution auto-injector (3000) comprising all features as recited in these claims, wherein the body comprises an outer body (base 3510) at a first end and an inner body at a second end (proximal end portion 3101), the second end comprising an end of the system configured to be positioned adjacent an injection site during use (Figure 16), a portion of the inner body positioned within a portion of the outer body, the first chamber (medicament volume 3237) and the second chamber (diluent volume 3236) positioned side by side and separated by a separator (bypass 3220). Regarding claim 3, Edwards reference, presented above, discloses applicant’s claimed reconstitution auto-injector (3000) comprising all features as recited in these claims, wherein the first chamber (medicament volume 3237) comprises a powder positioned therein (paragraph 0004), and the second chamber (diluent volume 3236) comprises a liquid positioned therein (paragraph 0004), and the separator comprises a flow channel (bypass 3200) providing fluid communication between the first chamber (medicament volume 3237) and the second chamber (diluent volume 3236), wherein the second chamber (diluent volume 3236) comprises a stopper (second elastomeric member 3225) positioned to obstruct the flow channel so that the first chamber (medicament volume 3237) and the second chamber (diluent volume 3236) are not in fluid communication in a first configuration (paragraph 0079-0080). Regarding claim 4, Edwards reference, presented above, discloses applicant’s claimed reconstitution auto-injector (3000) comprising all features as recited in these claims, further comprising a first power source and a second power source (springs 3390, 3420), the first power source in communication with a first plunger (first elastomeric 3221) and configured to move the plunger away from the first power source, and the second power source in communication with a second plunger (transfer member 3600) and configured to move the plunger away from the second power source (see Figures 12-18). Regarding claim 5, Edwards reference, presented above, discloses applicant’s claimed reconstitution auto-injector (3000) comprising all features as recited in these claims, wherein the second power source is configured to activate upon pressure on the inner body as the system is pressed against an injection site of a patient. Regarding claim 6, Edwards reference, presented above, discloses applicant’s claimed reconstitution auto-injector (3000) comprising all features as recited in these claims, the second power source comprising a first compressed spring (spring 3390) configured to release upon activation and extend to move a second plunger rod and the second plunger away from the second power source and compress a volume of the second chamber comprising the liquid (paragraph 0082-0083). Regarding claim 7, Edwards reference, presented above, discloses applicant’s claimed reconstitution auto-injector (3000) comprising all features as recited in these claims, the first power source comprising a second compressed spring (spring 3420) configured to release upon activation and extend to move the first plunger rod and the first plunger away from the first power source and compress a volume of the first chamber (paragraph 0082-0083). Regarding claim 8, Edwards reference, presented above, discloses applicant’s claimed reconstitution auto-injector (3000) comprising all features as recited in these claims, further comprising an actuator (actuator assembly 3500) between the first plunger and the first power source configured to release the first spring as the first plunger is moved toward the first power source (paragraph 0082-0083). Regarding claim 9, Edwards reference, presented above, discloses applicant’s claimed reconstitution auto-injector (3000) comprising all features as recited in these claims, further comprising a needle (3216), a stopper (third elastomeric member 3229), and an end cap (stopper 3254), wherein the stopper (third elastomeric member 3229) is positioned within the first chamber adjacent the end cap (Figure 14), and the needle is configured to extend into the stopper and to move through the stopper and end cap (see Figure 17). Regarding claim 10, Edwards reference, presented above, discloses applicant’s claimed reconstitution auto-injector (3000) comprising all features as recited in these claims, further comprising a safety cap (safety lock 3700). Regarding independent claim 11, Edwards discloses applicant’s claimed method of using a reconstitution auto-injector, comprising: providing the reconstitution auto-injector (3000); activating the reconstitution auto-injector (3000); reconstituting a drug in a powder form into a reconstituted drug mixture; and injecting the reconstituted drug mixture into a patient (paragraph 0044). Regarding claim 12, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, wherein the reconstitution auto-injector comprises a powder (paragraph 0004) contained in a first chamber (medicament volume 3237) and a liquid (paragraph 0004) contained in a second chamber (diluent volume 3236), wherein the powder and liquid are maintained separate from each other in a first configuration prior to use (see Figure 14). Regarding claim 13, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, wherein activating the reconstitution auto-injector comprises pressing the reconstitution auto-injector against a skin of the patient to automatically trigger the reconstitution and the injection (paragraph 0082). Regarding claim 14, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, wherein the activation comprising releasing a second compressed spring (3420) to move a second plunger (transfer member 3600) in a direction away from the second compressed spring and toward an injection site (Figures 12-18). Regarding claim 15, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, further comprising opening a flow channel (bypass 3220) between the second chamber (diluent volume 32363) and the first chamber (medicament volume 3237) so that as the second plunger moves by the second spring, the liquid moves into the first chamber (paragraphs 0054 & 0080). Regarding claim 16, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, further comprising applying a gas through the flow channel after the liquid from the second chamber moves into the first chamber to agitate the liquid and reconstitute the powder into the liquid creating a reconstituted mixture (paragraph 0039), and blocking the flow channel with the second plunger (2nd plunger moves and transfers movement to block 3220, Figure 18). Regarding claim 17, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, further comprising actuating a first compressed spring (3390) by moving a first plunger (first elastomeric member 3221) in the first chamber as the first chamber is filled with the liquid from the second chamber, thereby releasing the first compressed spring and applying a force on the first plunger to move the first plunger away from the first spring and toward the injection site (Figures 12-18). Regarding claim 18, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, further comprising moving a needle (3216) within the first chamber with the first plunger through a stopper (third elastomeric member 3229) and out an end cap (stopper 3254). Regarding claim 19, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, further comprising dispelling gas contained within the first chamber through the needle after an end of the needle exits the stopper (paragraph 0034), while the end of the needle is within a gap (inner volume 3259) created by the end cap and before the end of the needle enters a skin of a patient (Figure 14). Regarding claim 20, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, further comprising moving the needle into the patient at the injection site while dispensing the reconstituted mixture into the patient (paragraph 0086). Regarding independent claim 21, Edwards discloses applicant’s claimed reconstitution auto-injector, comprising a body having: a first chamber (medicament volume 3237) configured to store a powder (paragraph 0004) therein; a first plunger (first elastomeric member 3221) within the first chamber; a first power source (spring 3390) configured to push the first plunger and reduce a volume within the first chamber (Figures 12-18); a first actuator (actuator assembly 3500) configured to trigger the first power source; a second chamber (diluent volume 3236) configured to store a liquid (paragraph 0004); a second plunger (transfer plunger 3600) in the second chamber; and a second power source (spring 3420) configured to push the second plunger and reduce a volume within the second chamber; a flow passage (bypass 3220) between the first chamber and the second chamber such that the liquid can flow into the first chamber when the second plunger is moved by the second power source (paragraph 0079-0080), wherein the first plunger, first actuator, and first power source are configured such that the activator automatically triggers the first power source when the liquid of the second chamber flows into the first chamber and moves the plunger in a first direction to increase the volume of the first chamber, and once triggered, the first power source pushes the first plunger in an opposite direction to reduce the volume within the first chamber (paragraph 0079-0080). Regarding claim 22, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, further comprising a stopper (second elastomeric member 3225) configured to cover the flow passage in a first configuration, and uncover the flow passage in a second configuration (paragraph 0079-0080), wherein the second configuration is configured to occur when the liquid in the second container is compressed by the second plunger after activation of the second power source (Figures 12-18). Regarding independent claim 23, Edwards discloses applicant’s claimed method of using a reconstitution auto-injector, comprising: providing the reconstitution auto-injector having a first chamber (medicament volume 3237) having a powder (paragraph 0004) contained therein, a second chamber (diluent volume 3236) having a liquid (paragraph 0004) contained therein, a first power source (spring 3390), and a second power source (spring 3420); activating the second power source to start the first power source and compress the liquid and flowing the liquid from the second chamber to the first chamber (paragraph 0079-0080); reconstituting a drug in a powder form into a reconstituted drug mixture (paragraph 0079-0080); and automatically activating the first power source to inject the reconstituted drug mixture into a patient (paragraphs 0082 & 0086). Regarding claim 24, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, wherein the automatic activation of the first power source is through a movement of a first plunger in a first direction, and the first power source is configured to move the first plunger, once activated, in a second direction opposite the first direction (paragraphs 0079-0080 & Figures 12-18). Regarding claim 25, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, wherein the activation of the second power source is by pressing the reconstitution auto-injector against a skin of a patient to activate the second power source (paragraphs 0082 & 0086). Regarding claim 26, Edwards reference, presented above, discloses applicant’s claimed method of using a reconstitution auto-injector, further comprising keeping the first chamber and second chamber out of fluid contact through a stopper (third elastomeric member 3229) over a flow channel (bypass 3220), and then permitting fluid flow from the second chamber to the first chamber by moving the stopper from the flow channel (paragraphs 0079-0080). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CAMTU TRAN NGUYEN whose telephone number is (571)272-4799. The examiner can normally be reached 9am-5pm, Monday-Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Rachael E Bredefeld can be reached at 571-270-5237. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CAMTU T NGUYEN/Examiner, Art Unit 3786
Read full office action

Prosecution Timeline

Oct 04, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773260
FUNDUS BUMPER MECHANICAL REFERENCE FOR EASIER MECHANISM DEPLOYMENT
2y 3m to grant Granted Oct 27, 2026
Patent 12757951
Partitioned PPE Mask or Respirator
4y 0m to grant Granted Oct 13, 2026
Patent 12734006
Connection Systems and Methods for Establishing Optical and Electrical Connections Through A Drape
2y 2m to grant Granted Sep 15, 2026
Patent 12728028
ANGULAR DIGITAL DEVICE FOR JOINT DEFORMITY OR IMBALANCE
1y 9m to grant Granted Sep 08, 2026
Patent 12721386
MASK
3y 10m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+38.6%)
3y 7m (~1y 6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 870 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month